Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer
Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Fadlo R. Khuri(American University of Beirut Medical Center), Gabriel Sica(Emory University), Nabil F. Saba(Emory University), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), Hyun S. Kim(Gwangju Institute of Science and Technology), Rabih Bechara(Piedmont Cancer Institute), Suresh S. Ramalingam(Emory University), Renea M. Stinson(Piedmont Cancer Institute), Chao Zhang(China Pharmaceutical University), Xingming Deng(Emory University), Michael R. Rossi(Piedmont Cancer Institute), Rathi N. Pillai(Emory University), Suchita Pakkala(Emory University), Shi-Yong Sun(Emory University), Guojing Zhang(Emory University)
Cited by 89
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
|Science|2007|1.4k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k